Prognostic value of pretreatment HER2 status in gastric cancer patients treated with postoperative chemoradiotherapy

Creative Commons License

Güler O. C., Kandaz M., Bahat Z., Canyılmaz E., Çakır E., Yöney A.

Turk Onkoloji Dergisi, cilt.32, sa.3, ss.89-94, 2017 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 3
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5505/tjo.2017.1598
  • Dergi Adı: Turk Onkoloji Dergisi
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.89-94
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

OBJECTIVE

Our purpose was to evaluate the prognostic or predictive importance of HER2 status in gastric cancer patients treated with postoperative chemoradiotherapy.

METHODS

We retrospectively analyzed the records of 49 gastric cancer patients treated with curative intent between April 2012 and January 2017; we also assessed the impact of HER2 status on prognosis and treatment outcomes.

RESULTS

During a median follow-up period of 14.6 months (range, 4.0–56.97 months), two patients (4%) had local recurrence and 21 patients (43%) developed distant metastasis. We found no statistically significant difference in metastasis frequency rates between HER2 negative (−) and positive (+) patients. The median overall survival (OS) and disease-free survival (DFS) for the whole group were 24.9 and 24.2 months, respectively. Although there was no significant difference in OS and DFS according to HER2 status, there was a negative trend in OS (p=0.451) and DFS (p=0.633) in HER2 (+) patients.

CONCLUSION

Although our study did not demonstrate any statistically significant importance of HER2 status in gastric cancer patients treated with postoperative chemoradiotherapy, the median OS of 13 months in HER2 (+) patients and 24.9 months for HER2 (−) patients warranted randomized trials with larger cohorts.

Keywords: Chemoradiotherapy; gastric cancer; HER2; radiotherapy.